Therapeutic Response
PD-L1 (TAP) >= 5% status confers therapeutic sensitivity to Cisplatin in combination with Fluorouracil and Tislelizumab in patients with Adenocarcinoma of the Gastroesophageal Junction.
Statements
| Source and description |
|---|
PD-L1 (TAP) >= 5% status confers therapeutic sensitivity to Cisplatin in combination with Fluorouracil and Tislelizumab in patients with Adenocarcinoma of the Gastroesophageal Junction.
| Source and description |
|---|